Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists

被引:51
|
作者
Maguire, David R. [1 ]
France, Charles P. [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
RHESUS-MONKEYS; SIGNAL-TRANSDUCTION; NEUROPATHIC PAIN; DELTA(9)-TETRAHYDROCANNABINOL; MORPHINE; BINDING; MODULATION; BRAIN; DISCRIMINATION; NALBUPHINE;
D O I
10.1124/jpet.114.216648
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cannabinoid receptor agonists, such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC), enhance the antinociceptive effects of mu-opioid receptor agonists, which suggests that combining cannabinoids with opioids would improve pain treatment. Combinations with lower efficacy agonists might be preferred and could avoid adverse effects associated with large doses; however, it is unclear whether interactions between opioids and cannabinoids vary across drugs with different efficacy. The antinociceptive effects of mu-opioid receptor agonists alone and in combination with cannabinoid receptor agonists were studied in rhesus monkeys (n 5 4) using a warm water tail withdrawal procedure. Etorphine, fentanyl, morphine, buprenorphine, nalbuphine, Delta(9)-THC, and CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl) phenol) each increased tail withdrawal latency. Pretreatment with doses of Delta(9)-THC (1.0 mg/kg) or CP 55,940 (0.032 mg/kg) that were ineffective alone shifted the fentanyl dose-effect curve leftward 20.6- and 52.9-fold, respectively, and the etorphine dose-effect curve leftward 12.4- and 19.6-fold, respectively. Delta(9)-THC and CP 55,940 shifted the morphine dose-effect curve leftward only 3.4- and 7.9-fold, respectively, and the buprenorphine curve only 5.4- and 4.1-fold, respectively. Neither Delta(9)-THC nor CP 55,940 significantly altered the effects of nalbuphine. Cannabinoid receptor agonists increase the antinociceptive potency of higher efficacy opioid receptor agonists more than lower efficacy agonists; however, because much smaller doses of each drug can be administered in combinations while achieving adequate pain relief and that other (e.g., abuse-related) effects of opioids do not appear to be enhanced by cannabinoids, these results provide additional support for combining opioids with cannabinoids to treat pain.
引用
收藏
页码:383 / 389
页数:7
相关论文
共 50 条
  • [1] The Role of Efficacy on the Interaction Between Mu Opioid Receptor Agonists and Cannabinoid Receptor Agonists
    Maguire, David R.
    France, Charles P.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S566 - S566
  • [2] Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio
    Maguire, David R.
    France, Charles P.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 819 : 217 - 224
  • [3] Role of efficacy at the mu opioid receptor on the interactions between mu opioid receptor agonists and cannabinoid receptor agonists: antinociception and drug discrimination
    Maguire, David
    France, Charles
    [J]. FASEB JOURNAL, 2014, 28 (01):
  • [4] Research and development of κ opioid receptor agonists and δ opioid receptor agonists
    Nagase, Hiroshi
    Saitoh, Akiyoshi
    [J]. PHARMACOLOGY & THERAPEUTICS, 2020, 205
  • [6] Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability
    France, Charles P.
    Maguire, David R.
    Minervini, Vanessa
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 151 - 152
  • [7] The Sigma1 Receptor Antagonist CM304 Enhances the Antinociceptive Effects of the Cannabinoid Receptor Agonists, but not Mu-Opioid Receptor Full Agonists in Mice
    Patel, Avi
    Obeng, Samuel
    Burns, Mallory
    Intagliata, Sebastiano
    Mottinelli, Marco
    Reeves, Morgan
    Behnke, Mira
    Restrepo, Luis
    Taylor, Victoria
    Pennington, Anna
    Jimenez, Lea
    Williamson, Morgan
    McCurdy, Christopher
    McMahon, Lance
    Hiranita, Takato
    [J]. FASEB JOURNAL, 2020, 34
  • [8] Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl
    Maguire, David R.
    France, Charles P.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 784 : 199 - 206
  • [9] Specific κ opioid receptor agonists
    Ronsisvalle, G
    Marrazzo, A
    Pasquinucci, L
    Prezzavento, O
    Pappalardo, M
    Vittorio, F
    [J]. FARMACO, 2001, 56 (1-2): : 121 - 125
  • [10] Different actions of opioid and cannabinoid receptor agonists in neuropathic pain
    Kohno, Tatsuro
    [J]. MOLECULAR PAIN, 2006, 2